GlassScriptPhysician profile
Michelle Ann Herman
NPI 1902804966
$1,881.82
in general payments reported to CMS, 2019-2025
30 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2020: $104 · 2021: $183 · 2022: $348 · 2023: $459 · 2024: $431 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $467.23 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $197.31 | 2023-2024 | Myfembree |
| Astellas Pharma US INC | $176.88 | 2023-2024 | Veozah |
| Hologic Sales and Service, LLC | $171.68 | 2021-2024 | Aptima, Thinprep 2000 Processor |
| Mayne Pharma Commercial LLC | $84.33 | 2022-2025 | |
| Myovant Sciences INC. | $69.08 | 2021-2022 | |
| Pfizer INC. | $66.36 | 2022-2024 | |
| Sage Therapeutics, LLC | $64.28 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $63.40 | 2023-2025 | |
| Amag Pharmaceuticals, INC. | $60.48 | 2019-2022 | |
| Aspira Women'S Health INC | $54.96 | 2024 | Ova1 |
| Coopersurgical, INC. | $39.69 | 2022-2025 | Paragard T 380a |
| Exeltis, USA INC. | $37.70 | 2022-2024 | Slynd |
| Millicent US INC | $37.23 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Organon LLC | $36.37 | 2024-2025 | Nexplanon |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $26.63 | 2019-2020 | |
| Smith+Nephew, INC. | $25.62 | 2025 | Pico 7 |
| Mimedx Group, INC. | $23.68 | 2025 | |
| Merck Sharp & Dohme LLC | $19.79 | 2023 | Gardasil 9 |
| Channel Medsystems, INC. | $18.78 | 2023 | |
| Myriad Women'S Health, INC. | $17.62 | 2023 | Myrisk |
| Novo Nordisk INC | $17.32 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $16.82 | 2022 | |
| Boston Scientific Corporation | $16.07 | 2019 | |
| Meditrina | $16.06 | 2025 | |
| Therapeuticsmd, INC. | $15.49 | 2022 | |
| Amgen INC. | $14.57 | 2019 | |
| Avion Pharmaceuticals | $13.69 | 2020 | |
| Mylan Pharmaceuticals INC. | $12.70 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.